Psychedelics Are Advancing in GAD, but None Are Yet Approved

What the “Pipeline” Label Hides

The phrase “psychedelic pipeline” groups compounds at very different stages of development, and important distinctions get lost in the shared label. What separates these agents is where each one stands. Some are approved, while others remain investigational. The supporting evidence also varies, ranging from published trials to early company press releases. For GAD, the evidence has grown quickly, but is still limited to early-phase trials.

Two Controlled Signals in Anxiety

GAD now has two positive controlled trials on different compounds. In a phase 2b dose-finding study, a single 100 µg dose of DT120 (lysergide) ODT, the compound published as MM120, produced a placebo-adjusted reduction of 5.0 points on the HAM-A at week 4, the prespecified primary endpoint, exceeding the trial’s 2.5-point threshold for clinical importance.¹ Separately, in a randomized, placebo-controlled phase 2 trial, psilocybin-assisted therapy delivered across two dosing sessions produced a statistically significant reduction in HAM-A scores versus placebo, according to company topline results that have not been peer reviewed.² Both agents remain investigational and are administered under supervision because of acute perceptual effects.

The One Approved Option Treats Depression, Not Anxiety

The one approved agent in this group is indicated for depression, not anxiety. Esketamine, an NMDA-receptor antagonist rather than a classic serotonergic psychedelic, carries a 2025 monotherapy indication for treatment-resistant depression, granted after it separated from placebo within 24 hours and held through day 28 in a randomized trial.³ No psychedelic, classic or otherwise, is approved for GAD.

Reading by Stage, Not by Label

Stage of evidence is the key distinction that matters most. Study results for GAD currently come from phase 2 trials. The lysergide program’s first phase 3 study recently reported positive topline results in depression.⁴ Its two phase 3 trials in GAD, Voyage (NCT06741228) and Panorama (NCT06809595), have not yet reported results, though topline data are expected in the third quarter of 2026. Enthusiasm has outrun evidence in this field before. In 2024 the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder, citing unresolved questions about study conduct and durability of effect.⁵ For GAD, the pipeline is real and growing, but its controlled signals are early, and no psychedelic is yet approved for anxiety.

References

1. Robison R, Barrow R, Conant C, et al. Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA. 2025;334(15):1358-1372.
2. Incannex Healthcare. Incannex reports positive results from phase 2 clinical trial of PSX-001 (Psi-GAD) for generalised anxiety disorder [press release]. August 26, 2025.
3. Janik A, Qiu X, Lane R, et al. Janik A, Qiu X, Lane R, et al. Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2025;82(9):877-887.
4. Definium Therapeutics. Positive topline results from the phase 3 Emerge study of DT120 orally disintegrating tablet (ODT) in major depressive disorder [press release]. June 22, 2026.
5. US Food and Drug Administration. Complete response letter, NDA 215455 (midomafetamine capsules). August 8, 2024.